Equities research analysts expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to announce sales of $10.98 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Collegium Pharmaceutical’s earnings. The highest sales estimate is $14.90 million and the lowest is $8.12 million. Collegium Pharmaceutical posted sales of $1.30 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 744.6%. The business is expected to report its next quarterly earnings report on Thursday, March 8th.

On average, analysts expect that Collegium Pharmaceutical will report full-year sales of $10.98 million for the current fiscal year, with estimates ranging from $18.50 million to $32.62 million. For the next fiscal year, analysts anticipate that the company will post sales of $300.17 million per share, with estimates ranging from $286.00 million to $318.63 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The business had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.13) EPS.

A number of analysts have recently weighed in on the company. HC Wainwright assumed coverage on Collegium Pharmaceutical in a research report on Monday, September 11th. They set a “buy” rating and a $21.00 price target on the stock. Piper Jaffray Companies reiterated a “buy” rating and set a $24.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, December 7th. Needham & Company LLC increased their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Jefferies Group increased their price target on Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Finally, Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Monday, November 13th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $23.50.

Shares of Collegium Pharmaceutical (COLL) opened at $17.91 on Wednesday. Collegium Pharmaceutical has a 1 year low of $7.37 and a 1 year high of $20.92.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the completion of the transaction, the chief executive officer now directly owns 558,987 shares of the company’s stock, valued at approximately $8,681,068.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $17.34, for a total value of $17,340,000.00. The disclosure for this sale can be found here. Insiders sold a total of 1,058,630 shares of company stock valued at $18,264,360 over the last three months. Corporate insiders own 25.76% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Sectoral Asset Management Inc boosted its stake in Collegium Pharmaceutical by 41.4% during the 2nd quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock valued at $22,627,000 after purchasing an additional 529,503 shares in the last quarter. Macquarie Group Ltd. boosted its stake in Collegium Pharmaceutical by 18.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,329,979 shares of the specialty pharmaceutical company’s stock valued at $13,951,000 after purchasing an additional 211,288 shares in the last quarter. Vanguard Group Inc. boosted its stake in Collegium Pharmaceutical by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after purchasing an additional 58,398 shares in the last quarter. Prudential Financial Inc. boosted its stake in Collegium Pharmaceutical by 62.8% during the 3rd quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock valued at $5,843,000 after purchasing an additional 214,860 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in Collegium Pharmaceutical by 773.8% during the 3rd quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock valued at $5,707,000 after purchasing an additional 481,771 shares in the last quarter. 79.98% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Expect Collegium Pharmaceutical, Inc. (COLL) Will Announce Quarterly Sales of $10.98 Million” was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/13/zacks-brokerages-expect-collegium-pharmaceutical-inc-coll-will-announce-quarterly-sales-of-10-98-million.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.